BCL2 and prostate carcinoma: It is not the only one action, indeed, silymarin/paclitaxel combination presents a synergistic effect to i) increase the Bax/Bcl-2 ratio by suppressing Bcl-2 gene expression into the prostate and gastric cancer cell lines [81,82]; ii) besides, they increased also the expression of TNFRSF10A, TNFRSF1A into the prostate cancer cells [82] and TNFR6 (Fas)/Fas ligand in gastric cancer cells [81] and thus inducing procaspase-8 and procaspase-3 activation and PARP cleaved.